Amylyx Pharmaceuticals Income Statement (2021-2026) | AMLX

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.28M0.55M21.68M84.55M108.41M102.69M75.96M88.64M1.02M0.42M-0.67M
Gross Profit (Quarter)
0.38M18.86M79.27M102.83M97.47M66.60M82.70M1.01M0.42M-0.67M
Operating items
Research & Development (Quarter)
10.93M12.85M13.39M21.46M24.26M24.91M22.81M24.19M29.04M30.04M44.91M36.61M23.35M21.24M22.89M22.12M27.22M19.86M21.21M27.61M
Selling, General & Administrative (Quarter)
7.66M10.35M14.92M26.35M29.99M29.94M40.84M44.01M43.39M48.72M52.24M57.76M21.65M17.83M17.10M15.68M15.64M16.17M15.39M16.17M
Restructuring Costs (Quarter)
22.85M
Other Operating Expenses (Quarter)
0.17M2.82M5.28M5.58M5.22M9.36M116.41M7.42M37.01M
Operating Expenses (Quarter)
18.59M23.20M28.32M47.81M54.25M55.03M66.48M73.48M78.02M83.97M106.52M210.77M75.26M76.08M39.99M37.80M42.86M36.03M36.60M43.78M
Operating Income (Quarter)
-18.59M-22.92M-28.32M-47.81M-54.25M-54.68M-44.59M-2.05M20.20M18.72M1.93M-122.13M-76.29M-75.66M210.63M-37.80M-42.86M-36.03M86.30M-43.78M
EBIT (Quarter)
-18.59M-22.92M-28.32M-47.81M-54.25M-54.68M-44.59M-2.05M20.20M18.72M1.93M-122.13M-76.29M-75.66M210.63M-37.80M-42.86M-36.03M86.30M-43.78M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.00M0.03M0.13M0.40M0.60M3.16M3.72M3.89M4.18M4.37M4.33M4.07M3.10M2.32M2.23M1.96M1.82M3.29M2.57M
Other Non Operating Income (Quarter)
-0.03M-0.23M-0.06M-0.02M-0.04M0.20M-0.69M-0.26M-0.08M-0.49M0.17M-0.75M-0.48M-0.14M0.16M-0.34M-0.55M-0.18M0.36M-0.07M
Non Operating Income (Quarter)
-3.33M-0.23M-5.25M-0.02M0.36M0.20M-1.82M3.46M-0.08M-0.49M4.54M3.58M-0.48M-0.14M0.16M-0.34M-0.55M1.64M1.06M2.50M
Net income details
EBT (Quarter)
-21.92M-23.14M-28.32M-47.70M-53.89M-53.88M-42.12M1.40M24.01M22.41M4.44M-118.55M-72.70M-72.70M-37.80M-35.91M-41.44M-34.39M111.62M-41.21M
Tax Provisions (Quarter)
0.15M0.20M-0.12M0.58M-0.17M1.93M1.52M1.75M0.24M-0.86M0.05M
Profit After Tax (Quarter)
-21.92M-23.14M-28.34M-47.85M-54.07M-53.76M-42.70M1.57M22.07M20.89M4.73M-118.79M-72.70M-72.70M-37.55M-35.91M-41.44M-34.39M-33.00M-41.28M
Income from Continuing Operations (Quarter)
-21.92M-23.14M-28.32M-47.85M-54.09M-53.76M-42.70M1.57M22.07M20.89M2.70M-118.79M-72.70M-72.70M-36.94M-35.91M-41.44M-34.39M111.58M-41.21M
Consolidated Net Income (Quarter)
-21.92M-23.14M-28.32M-47.85M-54.09M-53.76M-42.70M1.57M22.07M20.89M2.70M-118.79M-72.70M-72.70M-36.94M-35.91M-41.44M-34.39M111.58M-41.21M
Income towards Parent Company (Quarter)
-21.92M-23.14M-28.32M-47.85M-54.09M-53.76M-42.70M1.57M22.07M20.89M2.70M-118.79M-72.70M-72.70M-36.94M-35.91M-41.44M-34.39M111.58M-41.21M
Net Income towards Common Stockholders (Quarter)
-21.92M-23.14M-28.32M-47.85M-54.09M-53.76M-42.70M1.57M22.07M20.89M2.70M-118.79M-72.70M-72.70M-36.94M-35.91M-41.44M-34.39M111.58M-41.21M
Additional items
EPS (Basic) (Quarter)
-3.41-3.42-4.15-0.93-0.93-0.92-0.620.020.330.310.07-1.75-1.07-1.07-0.54-0.42-0.46-0.37-0.28-0.37
EPS (Weighted Average and Diluted) (Quarter)
-3.41-3.42-4.15-0.93-0.93-0.92-0.620.020.310.300.07-1.75-1.07-1.07-0.54-0.42-0.46-0.37-0.28-0.37
Shares Outstanding (Weighted Average) (Quarter)
6.43M6.76M6.59M51.60M58.28M56.16M58.50M66.72M67.23M67.12M67.23M67.85M68.02M67.99M68.14M85.70M87.43M89.42M94.57M110.56M
Shares Outstanding (Diluted Average) (Quarter)
6.43M6.48M6.59M51.60M58.28M56.16M58.50M70.86M69.99M67.85M68.02M68.09M68.14M85.70M87.43M89.42M94.57M110.56M
EBITDA (Quarter)
-18.59M-22.92M-28.32M-47.81M-54.25M-54.68M-44.59M-2.05M20.20M18.72M1.93M-122.13M-76.29M-75.66M210.63M-35.81M-42.86M-36.03M86.30M-41.45M
Shares Outstanding (Quarter)
6.44M6.80M7.02M57.86M58.53M58.53M66.51M67.10M67.35M67.51M67.71M67.98M68.08M68.55M68.63M89.08M89.16M109.77M109.88M111.03M
Tax Rate (Quarter)
-0.31-0.370.23-1.37-12.128.056.7739.28-0.202.270.04